摘要
目的:探讨二肽基肽酶-4(DPP-4)抑制剂在2型糖尿病(T2DM)合并非酒精性脂肪肝(NAFLD)患者中的应用效果。方法:选取2018年1月-2019年2月在本院治疗的T2DM合并NAFLD患者164例,根据治疗方案分为观察组(n=88)和对照组(n=76)。对照组给予常规治疗,观察组在对照组基础上加用DPP-4抑制剂,观察两组治疗效果。结果:治疗后,两组丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)和谷氨酰胺转肽酶(GGT)均较治疗前改善(P<0.05),且观察组ALT、AST和GGT均明显低于对照组(P<0.05)。治疗后,两组总胆固醇(TC)、甘油三酯(TG)、空腹血糖(FPG)和糖化血红蛋白(HbA1c)均较治疗前改善(P<0.05),且观察组TC、FPG和HbA1c均明显低于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:DPP-4抑制剂治疗T2DM合并NAFLD中有较好的效果,能明显改善患者肝功能、血脂及血糖水平。
Objective:To investigate the clinical effect of dipeptidyl peptidase-4(DPP-4)inhibitor in type 2 diabetes mellitus(T2DM)with nonalcoholic fatty liver disease(NAFLD).Method:A total of 164 patients with T2DM complicated with NAFLD who treated in our hospital from January 2018 to February 2019 were selected.According to the treatment plan,they were divided into observation group(n=88)and control group(n=76).The control group was given routine treatment,and the observation group was added with DPP-4 inhibitor on the basis of the control group,the treatment effects of two groups were observed.Result:After treatment,alanine aminotransferase(ALT),aspartic aminotransferase(AST)and glutamine transpeptidase(GGT)in two groups were improved compared with before treatment(P<0.05),ALT,AST and GGT in the observation group were significantly lower than those in the control group(P<0.05).After treatment,total cholesterol(TC),triglyceride(TG),fasting plasma glucose(FPG)and glycosylated hemoglobin(HbA1c)in two groups were improved compared with before treatment(P<0.05),TC,FPG and HbA1c in the observation group were significantly lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between two groups(P>0.05).Conclusion:DPP-4 inhibitor has a good effect in the treatment of T2DM with NAFLD,and can significantly improve the liver function,blood lipid and blood glucose levels of patients.
作者
方宁
林彩战
FANG Ning;LIN Caizhan(Yangdong District People’s Hospital,Yangjiang 529500,China)
出处
《中国医学创新》
CAS
2021年第9期153-157,共5页
Medical Innovation of China
关键词
二肽基肽酶-4抑制剂
2型糖尿病
非酒精性脂肪肝
Dipeptidyl peptidase-4 inhibitor
Type 2 diabetes mellitus
Nonalcoholic fatty liver disease
